CAR-TCR

Harnessing Disruptive CAR & TCR Based Cell Technologies to Supercharge Safe, Effective & Globally Accessible Cell Immunotherapies in Oncology & Beyond.

The 6th Annual CAR-TCR Summit returns in 2021 as the industry-leading comprehensive forum with one goal: to engineer a disease-free world.
August 30-September 2, 2021 | Digital - EDT

Latest from CAR-TCR

Chris Bond, PhD, on Allogeneic and Induced Pluripotent Stem Cell Approaches to Cell Therapy

October 24, 2022

Video

The senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.

Nick Boyle, PhD, on Advantages of In Vivo CAR Therapies

October 10, 2022

Video

The chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.

Evan Zynda, PhD, on Optimizing Manufacturing to Increase Access to Cell Therapy

October 08, 2022

Video

The senior scientist at Thermo Fisher Scientific discussed the company’s approach to scaling and strategic partnerships.

Marty Giedlin, PhD, on Advantages of Allogeneic NK Cell Therapy Approaches

September 29, 2022

Video

The senior vice president of Technical Operations at Senti Biosciences discussed the company’s NK cell logic-gating platform and allogeneic approach.

Leaping the Next Hurdle in CAR T-Cell Therapies

September 28, 2022

Video

Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.

Switchable CAR-T Shows Promise in B-Cell Malignancies

September 22, 2022

Article

Interim data showed a 78% overall response rate and a 67% complete response rate.

Zevor-Cel Yields 100% ORR in R/R Multiple Myeloma

September 22, 2022

Article

Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.

Poseida’s CAR-T Cell Therapy for Prostate Cancer Shows Promising Durable Response in Phase 1

September 01, 2021

Article

The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.

2021 CAR-TCR Summit Elevates Industry Expertise in Cell Therapies

August 27, 2021

Article

The 4-day virtual conference will feature plenary presentations, workshops, and bootcamps led by cell therapy industry leaders with expertise in discovery, development, manufacturing, and more.